Liqmeds Worldwide Limited

Zydus Lifesciences Limited has been expanding the number of indications for which its novel molecules are being studied as it follows the "pipeline-in-a-drug" model successfully implemented by others

Zydus Lifesciences expects $100m in sales from specialty products like drugs for rare/orphan diseases over three to five years and will continue to pursue organic opportunities as well as acquisition

Zydus Lifesciences Limited expects $100m in sales from specialty products like drugs for rare/orphan diseases over three to five years and will continue to pursue organic opportunities as well as acq